URINARY INCONTINENCE IN DETAIL DEFN TYPES CF INVESTIGATION MANGEMNT IN DETAIL

Reading Document
Medical Text Search

urinary incontinence definition types classification stress urge overflow

Medical Text Search

urinary incontinence clinical features investigation management treatment

GradeResponse
GradeResponse
I have initial results. Let me now compile a comprehensive, detailed answer drawing on retrieved content and my broad clinical knowledge.

Urinary Incontinence — Comprehensive Review


1. DEFINITION

Urinary incontinence (UI) is defined as the involuntary (unintentional) loss of urine that is objectively demonstrable and constitutes a social or hygienic problem (ICS — International Continence Society definition).
  • It is a symptom, a sign, and a condition
  • Prevalence ranges from ~11% in men aged 60–64 years up to 31% in men ≥85 years, and affects up to 32% of men with LUTS; in women it is even more prevalent (20–40%)
  • It significantly impairs quality of life, leading to psychological distress, social isolation, and skin complications

2. TYPES / CLASSIFICATION

A. Stress Urinary Incontinence (SUI)

  • Definition: Involuntary leakage of urine on effort, exertion, sneezing, or coughing — i.e., when intra-abdominal pressure exceeds urethral closing pressure without detrusor contraction
  • Mechanism: Deficient urethral sphincter mechanism ± urethral hypermobility (in women: weakened pelvic floor due to childbirth, menopause; in men: post-prostatectomy)
  • Subtypes:
    • Type I: Leaks with moderate increases in abdominal pressure, no significant urethral hypermobility
    • Type II: Urethral hypermobility (bladder neck descent > 2 cm on Valsalva)
    • Type III: Intrinsic sphincter deficiency (ISD) — severe, continuous leakage at rest or minimal activity

B. Urge Urinary Incontinence (UUI)

  • Definition: Involuntary leakage of urine accompanied or immediately preceded by a strong sudden urge to void
  • Mechanism: Involuntary detrusor (bladder muscle) contractions (Overactive Bladder, OAB wet)
  • Causes: Idiopathic (most common), UTI, bladder stones, neurological disorders (stroke, MS, Parkinson's), bladder carcinoma in situ
  • Characteristics: Large volume leaks, frequency, nocturia, urgency

C. Mixed Urinary Incontinence (MUI)

  • Definition: Involuntary leakage associated with both urgency and exertion/effort/sneezing/coughing
  • Most common type in women
  • Treat the predominant component first

D. Overflow Incontinence

  • Definition: Involuntary leakage from an overdistended bladder due to failure to empty
  • Mechanism: Chronic urinary retention → intravesical pressure exceeds urethral resistance
  • Causes:
    • Obstructive: BPH, urethral stricture, bladder neck obstruction
    • Acontractile bladder: Diabetic cystopathy, pelvic surgery (nerve damage), spinal cord injury (lower motor neurone)
  • Features: Continuous dribbling, sensation of incomplete emptying, high post-void residual (PVR), paradoxical incontinence

E. Functional Incontinence

  • Leakage due to inability to reach the toilet in time despite a normal urinary tract
  • Causes: Dementia, severe mobility impairment, depression, sedation
  • Common in elderly institutionalized patients

F. Total (Continuous) Incontinence

  • Continuous leakage of urine at all times, day and night
  • Causes: Vesicovaginal fistula (VVF), ureterovaginal fistula, epispadias, ectopic ureter

G. Nocturnal Enuresis

  • Involuntary voiding during sleep; can be primary or secondary

H. Post-Micturition Dribble

  • Involuntary loss of urine immediately after finishing voiding; common in men (bulbar urethral pooling)

3. CLINICAL FEATURES

History

FeatureSuggests
Leakage with cough/sneeze/exerciseSUI
Urgency preceding leakageUUI/OAB
Continuous dribblingOverflow or total incontinence
Poor stream, hesitancy, strainingObstructive overflow
Neurological symptomsNeurogenic UI
Pelvic surgery/radiotherapySphincter damage, fistula
Obstetric history (multiparity)SUI/MUI
Postmenopausal statusUrogenital atrophy → SUI/UUI
Haematuria, dysuria, nocturiaUTI, malignancy
Drug historyDiuretics (UI), alpha-blockers (SUI), anticholinergics (retention)

Symptom Assessment Tools

  • ICIQ-UI SF (International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form) — gold standard questionnaire
  • Bladder diary (frequency-volume chart over 3 days): records voiding times, volumes, urgency episodes, incontinence episodes, fluid intake

Physical Examination

  • General: BMI (obesity worsens SUI), mobility, cognitive function
  • Abdominal: Palpable bladder (retention/overflow), lower abdominal masses
  • Pelvic (women):
    • Atrophic vaginitis (pale, dry mucosa)
    • Pelvic organ prolapse (cystocele, rectocele, uterine prolapse)
    • Urethral hypermobility / mucosal prolapse
    • Cough stress test: ask patient to cough with a full bladder in lithotomy position — immediate leakage = SUI; delayed = UUI
    • Q-tip test: measures urethral hypermobility (>30° deflection = positive)
  • Rectal examination (men):
    • Prostate size, consistency (BPH vs. malignancy)
    • Anal sphincter tone (neurological assessment)
  • Neurological: Lower limb reflexes, perineal sensation, bulbocavernosus reflex, saddle anaesthesia (cauda equina)

4. INVESTIGATIONS

First-Line (All Patients)

InvestigationPurpose
Urinalysis ± urine cultureExclude UTI, haematuria, glycosuria (DM)
Bladder diary (3-day)Quantify frequency, volumes, episodes; diagnose OAB vs. polyuria
Post-void residual (PVR) ultrasound>150–200 mL = significant retention; overflow
Pad test (1-hour or 24-hour)Quantify urine loss; >1 g/hr = positive; grades severity
Renal function (U&E, creatinine)Bilateral hydronephrosis due to chronic retention

Second-Line / Specialist Investigations

Urodynamic Studies (UDS) — Gold Standard for Objective Diagnosis

Indicated when: diagnosis is uncertain, conservative/medical treatment has failed, prior to surgery, suspected neurogenic bladder
ComponentMeasures
UroflowmetryFlow rate, voided volume, pattern (obstructed = plateau curve)
Cystometry (filling)Detrusor overactivity (involuntary contractions), compliance, capacity, first desire/urgency
Pressure-flow studyDistinguishes obstruction from detrusor underactivity
Urethral pressure profile (UPP)Functional urethral length, maximum urethral closure pressure (low in ISD)
Video-urodynamicsCombines fluoroscopy with urodynamics — best for complex/neurogenic cases
Leak-point pressure (LPP)Abdominal LPP: <60 cmH₂O = ISD; Detrusor LPP used in neurogenic UI

Imaging

TestIndication
Renal/bladder USSPVR, hydronephrosis, bladder wall thickness, masses
CT urogram / IVUHaematuria workup, fistula, ectopic ureter
MRI pelvisPelvic floor anatomy, sphincter defects, neurogenic causes
Voiding cystourethrogram (VCUG)VVF, urethral diverticulum, VUR

Endoscopy

TestIndication
CystoscopyHaematuria, bladder tumour, CIS, stones, fistula, urethral pathology

Neurophysiology (Neurogenic UI)

  • EMG of pelvic floor / sphincter
  • Nerve conduction studies
  • Spinal MRI

5. MANAGEMENT IN DETAIL

General Principles

  • Treat reversible causes first (DIAPERS mnemonic):
    • Delirium, Infection, Atrophic urethritis/vaginitis, Pharmaceuticals, Psychological, Excessive urine output, Restricted mobility, Stool impaction

A. CONSERVATIVE MANAGEMENT (First-Line for All Types)

1. Lifestyle Modifications

  • Weight reduction: 5–10% weight loss → significant reduction in UI episodes (strong evidence)
  • Fluid management: Optimize intake (1.5–2 L/day); avoid caffeine, alcohol, carbonated drinks (bladder irritants)
  • Smoking cessation: Reduces chronic cough (worsens SUI)
  • Treat constipation: Reduces pelvic floor pressure
  • Avoid precipitating medications (diuretics, alpha-blockers, CCBs)

2. Bladder Training (UUI/MUI)

  • Scheduled voiding with progressive delay of voiding interval by 15–30 min per week
  • Target: voiding every 3–4 hours
  • Duration: minimum 6 weeks
  • Effective in UUI: ~50–80% improvement

3. Pelvic Floor Muscle Training (PFMT) — Kegel Exercises (SUI/MUI)

  • Most effective conservative treatment for SUI
  • Protocol: 8–12 contractions, 3 sets/day, minimum 15–20 weeks
  • Taught with biofeedback, electrical stimulation, or physiotherapy supervision
  • Success rates: 60–70% cure/improvement in SUI
  • Also effective in UUI (inhibitory reflex on detrusor contraction)

4. Prompted/Timed Voiding

  • For functionally impaired patients (dementia, mobility issues)
  • Caregiver-assisted toileting at fixed intervals

5. Containment Products

  • Absorbent pads, catheters (only as last resort) — manage but do not treat

B. PHARMACOLOGICAL MANAGEMENT

Stress Urinary Incontinence

DrugClassMechanismNotes
DuloxetineSNRIIncreases sphincter tone via pudendal nerve (serotonin + noradrenaline)2nd line; reduces leak episodes ~50%; SE: nausea, discontinuation syndrome
Topical oestrogenOestrogenRestores urogenital atrophyPostmenopausal women; reduces symptoms; not systemic HRT
Alpha-adrenergic agonists (pseudoephedrine)SympathomimeticIncreases urethral toneLimited use; cardiovascular SE

Urge Urinary Incontinence / OAB

DrugClassExamplesNotes
AntimuscarinicsM2/M3 antagonistsOxybutynin, Tolterodine, Solifenacin, Darifenacin, Fesoterodine, TrospiumFirst-line; reduce detrusor contractions; SE: dry mouth, constipation, blurred vision, cognitive impairment (especially in elderly — prefer Trospium or Darifenacin)
Beta-3 adrenoceptor agonistsβ3 agonistMirabegronRelaxes detrusor; equivalent efficacy to antimuscarinics; SE: hypertension, nasopharyngitis; preferred in elderly/cognitive impairment
CombinationAntimuscarinic + β3Solifenacin + Mirabegron (Vibegron)Superior to monotherapy

Overflow Incontinence

DrugIndication
Alpha-blockers (Tamsulosin, Alfuzosin)BPH-related obstruction
5-alpha reductase inhibitors (Finasteride, Dutasteride)BPH (long-term volume reduction)
Bethanechol (cholinergic)Acontractile detrusor (limited evidence)
Intermittent self-catheterisation (ISC)Neurogenic/acontractile bladder — gold standard

C. MINIMALLY INVASIVE / SURGICAL MANAGEMENT

Stress Urinary Incontinence

ProcedureDescriptionOutcome
Mid-urethral sling (MUS)TVT / TOTTension-free vaginal tape (retropubic) or transobturator tape; polypropylene mesh supports mid-urethraGold standard for SUI in women; >80–90% cure rates
Bulking agents (Injection)Periurethral injection of bulking agents (Macroplastique, Bulkamid, collagen) to improve coaptationLess invasive; ~60% efficacy; suitable for elderly/high-risk; requires repeat
Burch colposuspensionLaparoscopic/open suspension of bladder neck to Cooper's ligamentEffective for urethral hypermobility; less used since MUS
Artificial urinary sphincter (AUS)Cuff around urethra/bladder neck, connected to pump/reservoirGold standard for men with post-prostatectomy SUI or ISD; >80% success
Male sling (AdVance, Virtue)Bulbar sling for mild-moderate male SUIAlternative to AUS in mild SUI
Pubovaginal slingAutologous fascia slingUsed when mesh contraindicated

Urge Urinary Incontinence / OAB (Refractory)

ProcedureDescriptionNotes
Intravesical Botulinum toxin A (OnabotulinumtoxinA)Cystoscopic injection (100–300 U) into detrusorHighly effective; ~70–80% improvement; SE: urinary retention (ISC required in ~20%); duration 6–12 months; repeat injections
Sacral neuromodulation (SNM) — InterStimImplanted electrode to S3 nerve root modulates voiding reflexOAB, UUI, non-obstructive retention; durable long-term results; reversible
Percutaneous tibial nerve stimulation (PTNS)Weekly 30-min sessions; posterior tibial nerve stimulationNon-invasive; office-based; 12-week course; efficacy ~60%
Augmentation cystoplastyDetubularized bowel segment added to bladder to increase capacityLast resort; requires ISC lifelong
Urinary diversionIleal conduit / continent diversionEnd-stage refractory cases

Overflow Incontinence

  • TURP / Laser prostatectomy: Gold standard for BPH obstruction
  • Urethrotomy / urethral dilation: Urethral stricture
  • Intermittent self-catheterisation (ISC): Neurogenic / acontractile bladder — first-line
  • Long-term urethral catheter / suprapubic catheter: When ISC not feasible

Fistula (VVF / Ureterovaginal)

  • Surgical repair (transabdominal or transvaginal; Latzko repair for VVF)
  • Ureteric reimplantation for ureterovaginal fistula

D. MANAGEMENT ALGORITHM SUMMARY

URINARY INCONTINENCE
│
├── History + Exam + Urinalysis + PVR + Bladder Diary
│
├── Reversible causes? → Treat first (DIAPERS)
│
├── TYPE?
│    ├── STRESS (SUI)
│    │    ├── Conservative: PFMT × 3 months
│    │    ├── Pharmacological: Duloxetine / Topical oestrogen
│    │    └── Surgical: TVT/TOT sling, AUS (men), bulking agents
│    │
│    ├── URGE (UUI/OAB)
│    │    ├── Conservative: Bladder training, PFMT
│    │    ├── Pharmacological: Antimuscarinics / Mirabegron
│    │    └── Interventional: Botox, SNM, PTNS
│    │
│    ├── MIXED (MUI)
│    │    └── Treat predominant component first
│    │
│    ├── OVERFLOW
│    │    ├── Obstructive: Alpha-blocker → TURP
│    │    └── Acontractile: ISC ± Bethanechol
│    │
│    └── FUNCTIONAL
│         └── Prompted voiding, mobility aids, caregiver support

E. SPECIAL POPULATIONS

Elderly

  • Minimize anticholinergics (cognitive effects) — prefer Mirabegron or Trospium
  • Prioritize functional and prompted voiding strategies
  • Fall risk from urgency — treat proactively

Neurogenic UI (Spinal cord injury, MS, Parkinson's, stroke)

  • Urodynamics mandatory before treatment
  • ISC is cornerstone for detrusor-sphincter dyssynergia or acontractile bladder
  • Botox widely used
  • Video-urodynamics for complex cases
  • Monitor upper tracts (renal USS, creatinine) regularly

Pregnancy

  • PFMT strongly recommended (prevents postpartum SUI)
  • Avoid pharmacological treatment in first trimester

Post-prostatectomy (Men)

  • PFMT within 24 hours of catheter removal
  • AUS = gold standard if severe/persistent SUI >12 months
  • Male sling for mild cases

6. COMPLICATIONS OF UNTREATED UI

  • Skin breakdown, perineal dermatitis, pressure ulcers
  • Recurrent UTIs
  • Depression, anxiety, social withdrawal
  • Falls and fractures (rushing to toilet in UUI)
  • Upper urinary tract damage (hydronephrosis, CKD) in chronic overflow

QUICK REFERENCE TABLE

FeatureSUIUUIOverflowFunctional
TriggerCough/exerciseUrgencyOverdistensionMobility/cognition
VolumeSmallLargeContinuous dribbleVariable
WarningNoneBriefNone/vagueTime to reach toilet
PVRNormalNormalHigh (>200 mL)Normal
UrodynamicsSUI on coughDetrusor overactivityLow flow, high PVRNormal
1st-line RxPFMTBladder training + antimuscarinics/MirabegronISC / alpha-blockersPrompted voiding
SurgeryMUS (TVT/TOT) / AUSBotox / SNMTURP / Urethrotomy

Sources: Non-Neurogenic Male Lower Urinary Tract Symptoms — EAU Guidelines (p. 59); Bailey & Love's Short Practice of Surgery, 28th Ed. (p. 1521); supplemented from ICS Standardisation Reports, EAU/NICE Incontinence Guidelines, Campbell-Walsh Urology.
This is a shared conversation. Sign in to Orris to start your own chat.